Abstract 2323: <i>Interferon regulatory factor-4</i> is transcriptionally regulated by NF-κB in peripheral T-cell lymphomas
Authors: Rebecca L. Boddicker, N. Sertac Kip, Luciana L. Almada, Julie C. Porcher, Deanna M. Grote, Stephen M. Ansell, Martin E. Fernandez-Zapico, Andrew L. Feldman
Journal: Cancer Research (2014)

Abstract Interferon regulatory factor-4 (IRF4) is a tightly-regulated transcription factor involved in growth and differentiation of normal lymphocytes. IRF4 is expressed in multiple lymphoid malignancies and its expression drives tumor growth. Thus, characterization of the molecular events regulating IRF4 levels is key to design any targeting strategy. Here, we define a novel regulatory mechanism controlling IRF4 expression in peripheral T-cell lymphoma (PTCL), an aggressive non-Hodgkin lymphoma with poor overall survival rates and high levels of this transcription factor. In normal T cells, IRF4 was induced upon external activation of protein kinase C (PKC) by phorbol myristate acetate and ionomycin, an effect reversed by the PKC inhibitor, enzastaurin. Unlike normal T cells, PTCL cells constitutively expressed IRF4 in the absence of external stimulation, and this expression was resistant to enzastaurin. To identify regulators of IRF4 expression in PTCL, we performed a pharmacological screen using inhibitors that targeted PKC-associated pathways, including mitogen-activated protein kinases, PI3K/AKT/mTOR, and NF-κB. Of the inhibitors tested, only the proteasome inhibitor, bortezomib, showed a decrease in IRF4 expression in a dose- and time-dependent manner. To confirm this result we used a more specific NF-κB inhibitor blocking IκB kinase, BMS-345541. This inhibitor dramatically reduced IRF4 expression by 95.6% (P&amp;lt;0.0001). We used cell-based assays to investigate further the role of NF-κB in the transcriptional regulation of IRF4. A reporter assay for the IRF4 promoter demonstrated reduced promoter activity by siRNA knockdown of RelB and p52 NF-κB subunits to 31.4% and 36.9% of control (P=0.009). IRF4 promoter activity also was inhibited 67.9% by IκBαΔN, a dominant negative inhibitor of NF-κB activity (P=0.002), and was increased 71% by siRNA knockdown of IκBα (P&amp;lt;0.05). Chromatin immunoprecipitation assays confirmed the occupancy of NF-κB subunits in the IRF4 promoter, and this interaction was diminished in the presence of BMS-345541. Finally, knockdown of RelB and p52 subunits had a tendency to decrease IRF4 gene expression by 24.4% and 27.3% (P=0.1). Taken together, these data demonstrate transcriptional regulation of IRF4 by the NF-κB family in PTCL, and suggest the NF-κB pathway may represent a therapeutic target for PTCLs with concurrent IRF4 and NF-κB expression. Citation Format: Rebecca L. Boddicker, N. Sertac Kip, Luciana L. Almada, Julie C. Porcher, Deanna M. Grote, Stephen M. Ansell, Martin E. Fernandez-Zapico, Andrew L. Feldman. Interferon regulatory factor-4 is transcriptionally regulated by NF-κB in peripheral T-cell lymphomas. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2323. doi:10.1158/1538-7445.AM2014-2323